377 related articles for article (PubMed ID: 25824727)
1. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
Yeganeh MZ; Sheikholeslami S; Hedayati M
Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
[TBL] [Abstract][Full Text] [Related]
2. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
3. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
5. Medullary thyroid carcinoma: a review on ethical considerations in treatment of children.
Nozhat Z; Hedayati M
J Pediatr Endocrinol Metab; 2016 Jun; 29(6):633-9. PubMed ID: 26974132
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
7. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
8. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
9. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
[TBL] [Abstract][Full Text] [Related]
10. Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma.
Yeganeh MZ; Sheikholeslami S; Dehbashi Behbahani G; Farashi S; Hedayati M
Tumour Biol; 2015 Jul; 36(7):5225-31. PubMed ID: 25694125
[TBL] [Abstract][Full Text] [Related]
11. A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.
Martins-Costa MC; Lindsey SC; Cunha LL; Carreiro-Filho FP; Cortez AP; Holanda ME; Farias JWM; Lima SB; Ferreira LAA; Maia Filho PC; Camacho CP; Furuzawa GK; Kunii IS; Dias-da-Silva MR; Martins JRM; Maciel RMB
Arch Endocrinol Metab; 2018; 62(6):623-635. PubMed ID: 30624503
[TBL] [Abstract][Full Text] [Related]
12. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
13. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes.
Bussières V; Roy S; Deladoey J; Rousseau É; St-Vil D; Piché N
J Pediatr Surg; 2018 Feb; 53(2):283-285. PubMed ID: 29336779
[TBL] [Abstract][Full Text] [Related]
15. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA; Pacini F; Robinson BG; Santoro M
J Clin Endocrinol Metab; 2013 Aug; 98(8):3149-64. PubMed ID: 23744408
[TBL] [Abstract][Full Text] [Related]
16. Hereditary medullary thyroid carcinoma: the management dilemma.
Zhou P; Liu J; Cheng SW; Wang B; Yang R; Peng L
Fam Cancer; 2012 Jun; 11(2):157-65. PubMed ID: 22183190
[TBL] [Abstract][Full Text] [Related]
17. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
18. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
Frank-Raue K; Rondot S; Raue F
Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.
Raue F; Frank-Raue K
Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
